Literature DB >> 28000060

A new strategy for full-length Ebola virus glycoprotein expression in E.coli.

Junjie Zai1,2, Yinhua Yi1,2, Han Xia1, Bo Zhang3, Zhiming Yuan4.   

Abstract

Ebola virus (EBOV) causes severe hemorrhagic fever in humans and non-human primates with high rates of fatality. Glycoprotein (GP) is the only envelope protein of EBOV, which may play a critical role in virus attachment and entry as well as stimulating host protective immune responses. However, the lack of expression of full-length GP in Escherichia coli hinders the further study of its function in viral pathogenesis. In this study, the vp40 gene was fused to the full-length gp gene and cloned into a prokaryotic expression vector. We showed that the VP40-GP and GP-VP40 fusion proteins could be expressed in E.coli at 16 °C. In addition, it was shown that the position of vp40 in the fusion proteins affected the yields of the fusion proteins, with a higher level of production of the fusion protein when vp40 was upstream of gp compared to when it was downstream. The results provide a strategy for the expression of a large quantity of EBOV full-length GP, which is of importance for further analyzing the relationship between the structure and function of GP and developing an antibody for the treatment of EBOV infection.

Entities:  

Keywords:  E.coli; Ebola virus (EBOV); glycoprotein (GP); prokaryotic expression

Mesh:

Substances:

Year:  2016        PMID: 28000060      PMCID: PMC8193397          DOI: 10.1007/s12250-016-3845-y

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  36 in total

1.  Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway.

Authors:  Nancy J Sullivan; Mary Peterson; Zhi-yong Yang; Wing-pui Kong; Heinricus Duckers; Elizabeth Nabel; Gary J Nabel
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.

Authors:  Karin Lövgren Bengtsson; Haifeng Song; Linda Stertman; Ye Liu; David C Flyer; Michael J Massare; Ren-Huan Xu; Bin Zhou; Hanxin Lu; Steve A Kwilas; Timothy J Hahn; Eloi Kpamegan; Jay Hooper; Ricardo Carrion; Gregory Glenn; Gale Smith
Journal:  Vaccine       Date:  2016-02-24       Impact factor: 3.641

3.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

Authors:  V E Volchkov; H Feldmann; V A Volchkova; H D Klenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

Authors:  P Pushko; M Bray; G V Ludwig; M Parker; A Schmaljohn; A Sanchez; P B Jahrling; J F Smith
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

5.  Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP.

Authors:  Takeshi Noda; Hiroshi Sagara; Emiko Suzuki; Ayato Takada; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Ectodomain shedding of the glycoprotein GP of Ebola virus.

Authors:  Olga Dolnik; Valentina Volchkova; Wolfgang Garten; Caroline Carbonnelle; Stephan Becker; Jörg Kahnt; Ute Ströher; Hans-Dieter Klenk; Viktor Volchkov
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

7.  Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.

Authors:  Jeffrey E Lee; Marnie L Fusco; Ann J Hessell; Wendelien B Oswald; Dennis R Burton; Erica Ollmann Saphire
Journal:  Nature       Date:  2008-07-10       Impact factor: 49.962

8.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

9.  Full-length Ebola glycoprotein accumulates in the endoplasmic reticulum.

Authors:  Suchita Bhattacharyya; Thomas J Hope
Journal:  Virol J       Date:  2011-01-12       Impact factor: 4.099

10.  Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.

Authors:  Nancy J Sullivan; Thomas W Geisbert; Joan B Geisbert; Devon J Shedlock; Ling Xu; Laurie Lamoreaux; Jerome H H V Custers; Paul M Popernack; Zhi-Yong Yang; Maria G Pau; Mario Roederer; Richard A Koup; Jaap Goudsmit; Peter B Jahrling; Gary J Nabel
Journal:  PLoS Med       Date:  2006-05-16       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.